By the same authors

From the same journal

Human papillomaviruses and cancer in Uganda

Research output: Contribution to journalArticlepeer-review

Standard

Human papillomaviruses and cancer in Uganda. / Newton, R.; Bousarghin, L.; Ziegler, J.; Casabonne, D.; Beral, V.; Mbidde, E.; Carpenter, L.; Parkin, D. M.; Wabinga, H.; Mbulaiteye, S.; Jaffe, H.; Touzé, A.; Coursaget, P.; Sembajwe, V.; Kalinaki, M.; Byansi, R.; Rwatooro, C.; Nambooze, S.; Tushimiere, B.; Byabazaire, N.; Bitamazire, E.; Katabira, E.; Mugerwa, J.; Tindyebura, D.; Ateenyi-Agaba, C.; Whitworth, J.; Richardson, B.; Reeves, G.; Weiss, R.; De Cock, K.

In: European journal of cancer prevention, Vol. 13, No. 2, 04.2004, p. 113-118.

Research output: Contribution to journalArticlepeer-review

Harvard

Newton, R, Bousarghin, L, Ziegler, J, Casabonne, D, Beral, V, Mbidde, E, Carpenter, L, Parkin, DM, Wabinga, H, Mbulaiteye, S, Jaffe, H, Touzé, A, Coursaget, P, Sembajwe, V, Kalinaki, M, Byansi, R, Rwatooro, C, Nambooze, S, Tushimiere, B, Byabazaire, N, Bitamazire, E, Katabira, E, Mugerwa, J, Tindyebura, D, Ateenyi-Agaba, C, Whitworth, J, Richardson, B, Reeves, G, Weiss, R & De Cock, K 2004, 'Human papillomaviruses and cancer in Uganda', European journal of cancer prevention, vol. 13, no. 2, pp. 113-118.

APA

Newton, R., Bousarghin, L., Ziegler, J., Casabonne, D., Beral, V., Mbidde, E., Carpenter, L., Parkin, D. M., Wabinga, H., Mbulaiteye, S., Jaffe, H., Touzé, A., Coursaget, P., Sembajwe, V., Kalinaki, M., Byansi, R., Rwatooro, C., Nambooze, S., Tushimiere, B., ... De Cock, K. (2004). Human papillomaviruses and cancer in Uganda. European journal of cancer prevention, 13(2), 113-118.

Vancouver

Newton R, Bousarghin L, Ziegler J, Casabonne D, Beral V, Mbidde E et al. Human papillomaviruses and cancer in Uganda. European journal of cancer prevention. 2004 Apr;13(2):113-118.

Author

Newton, R. ; Bousarghin, L. ; Ziegler, J. ; Casabonne, D. ; Beral, V. ; Mbidde, E. ; Carpenter, L. ; Parkin, D. M. ; Wabinga, H. ; Mbulaiteye, S. ; Jaffe, H. ; Touzé, A. ; Coursaget, P. ; Sembajwe, V. ; Kalinaki, M. ; Byansi, R. ; Rwatooro, C. ; Nambooze, S. ; Tushimiere, B. ; Byabazaire, N. ; Bitamazire, E. ; Katabira, E. ; Mugerwa, J. ; Tindyebura, D. ; Ateenyi-Agaba, C. ; Whitworth, J. ; Richardson, B. ; Reeves, G. ; Weiss, R. ; De Cock, K. / Human papillomaviruses and cancer in Uganda. In: European journal of cancer prevention. 2004 ; Vol. 13, No. 2. pp. 113-118.

Bibtex - Download

@article{d71a0431d1bb4e10bc2d30d286f5e245,
title = "Human papillomaviruses and cancer in Uganda",
abstract = "In a case-control study in Uganda, we examined associations between different cancer sites or types in relation to antibodies against human papillomaviruses (HPV)-16, -18 and -45. For each cancer site or type, the control group comprised all other cancers excluding those known, or thought to be associated with HPV infection (cancers of the uterine cervix, penis and eye). Among controls the seroprevalence of antibodies was 11% (68/616) against HPV-16, 5% (29/605) against HPV-18 and 6% (35/605) against HPV-45. Antibodies against HPV-16 were significantly associated with only two cancers: uterine cervix [prevalence of antibodies 27% (51/191); odds ratio (OR) 2.0, 95% confidence interval (CI) 1.2-3.1, P=0.01] and penis [prevalence of antibodies 27% (4/15); OR 6.4.95% CI 1.7-24.3, P=0.01]. For both cancers, the risk increased with increasing anti-HPV-16 antibody titre (Ptrend=0.01 for each). No cancer site or type was significantly associated with antibodies against HPV-18 and -45.",
keywords = "Cancer, Human papillomavirus (HPV), Uganda",
author = "R. Newton and L. Bousarghin and J. Ziegler and D. Casabonne and V. Beral and E. Mbidde and L. Carpenter and Parkin, {D. M.} and H. Wabinga and S. Mbulaiteye and H. Jaffe and A. Touz{\'e} and P. Coursaget and V. Sembajwe and M. Kalinaki and R. Byansi and C. Rwatooro and S. Nambooze and B. Tushimiere and N. Byabazaire and E. Bitamazire and E. Katabira and J. Mugerwa and D. Tindyebura and C. Ateenyi-Agaba and J. Whitworth and B. Richardson and G. Reeves and R. Weiss and {De Cock}, K.",
year = "2004",
month = apr,
language = "English",
volume = "13",
pages = "113--118",
journal = "European journal of cancer prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Human papillomaviruses and cancer in Uganda

AU - Newton, R.

AU - Bousarghin, L.

AU - Ziegler, J.

AU - Casabonne, D.

AU - Beral, V.

AU - Mbidde, E.

AU - Carpenter, L.

AU - Parkin, D. M.

AU - Wabinga, H.

AU - Mbulaiteye, S.

AU - Jaffe, H.

AU - Touzé, A.

AU - Coursaget, P.

AU - Sembajwe, V.

AU - Kalinaki, M.

AU - Byansi, R.

AU - Rwatooro, C.

AU - Nambooze, S.

AU - Tushimiere, B.

AU - Byabazaire, N.

AU - Bitamazire, E.

AU - Katabira, E.

AU - Mugerwa, J.

AU - Tindyebura, D.

AU - Ateenyi-Agaba, C.

AU - Whitworth, J.

AU - Richardson, B.

AU - Reeves, G.

AU - Weiss, R.

AU - De Cock, K.

PY - 2004/4

Y1 - 2004/4

N2 - In a case-control study in Uganda, we examined associations between different cancer sites or types in relation to antibodies against human papillomaviruses (HPV)-16, -18 and -45. For each cancer site or type, the control group comprised all other cancers excluding those known, or thought to be associated with HPV infection (cancers of the uterine cervix, penis and eye). Among controls the seroprevalence of antibodies was 11% (68/616) against HPV-16, 5% (29/605) against HPV-18 and 6% (35/605) against HPV-45. Antibodies against HPV-16 were significantly associated with only two cancers: uterine cervix [prevalence of antibodies 27% (51/191); odds ratio (OR) 2.0, 95% confidence interval (CI) 1.2-3.1, P=0.01] and penis [prevalence of antibodies 27% (4/15); OR 6.4.95% CI 1.7-24.3, P=0.01]. For both cancers, the risk increased with increasing anti-HPV-16 antibody titre (Ptrend=0.01 for each). No cancer site or type was significantly associated with antibodies against HPV-18 and -45.

AB - In a case-control study in Uganda, we examined associations between different cancer sites or types in relation to antibodies against human papillomaviruses (HPV)-16, -18 and -45. For each cancer site or type, the control group comprised all other cancers excluding those known, or thought to be associated with HPV infection (cancers of the uterine cervix, penis and eye). Among controls the seroprevalence of antibodies was 11% (68/616) against HPV-16, 5% (29/605) against HPV-18 and 6% (35/605) against HPV-45. Antibodies against HPV-16 were significantly associated with only two cancers: uterine cervix [prevalence of antibodies 27% (51/191); odds ratio (OR) 2.0, 95% confidence interval (CI) 1.2-3.1, P=0.01] and penis [prevalence of antibodies 27% (4/15); OR 6.4.95% CI 1.7-24.3, P=0.01]. For both cancers, the risk increased with increasing anti-HPV-16 antibody titre (Ptrend=0.01 for each). No cancer site or type was significantly associated with antibodies against HPV-18 and -45.

KW - Cancer

KW - Human papillomavirus (HPV)

KW - Uganda

UR - http://www.scopus.com/inward/record.url?scp=2342481927&partnerID=8YFLogxK

M3 - Article

C2 - 15100577

AN - SCOPUS:2342481927

VL - 13

SP - 113

EP - 118

JO - European journal of cancer prevention

JF - European journal of cancer prevention

SN - 0959-8278

IS - 2

ER -